<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SYSU-CHINA skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SYSU-CHINA</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="nav"><UL class="menu" style="left:260px;margin:16px 0 0 10px;"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA">HOME</A></LI><LI><A href="#">PROJECT</A></LI><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Description">Description</A></LI></UL><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Design">Design</A></LI></UL><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Demonstrate">Demonstrate</A></LI></UL><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Applied_Design">Applied Design</A></LI></UL><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Notebook">Notebook&amp;Experiments</A></LI></UL><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/InterLab">InterLab</A></LI></UL><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Measurement">Measurement</A></LI></UL><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Model">MODEL</A></LI><LI><A href="#">PARTS</A></LI><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Parts">Parts Overview</A></LI><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Basic_Part">Basic Parts</A></LI></UL><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Improve">Improve</A></LI></UL><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Safety">SAFETY</A></LI><LI><A href="#">HUMAN PRACTICES</A></LI><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Human_Practices">Human Practices</A></LI><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Public_Engagement">Public Engagement</A></LI></UL><LI><A href="#">TEAM</A></LI><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Team">Team Members</A></LI><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Attributions">Attributions</A></LI></UL><UL class="submenu"><LI><A href="https://2018.igem.org/Team:SYSU-CHINA/Collaborations">Collaborations</A></LI></UL></DIV><DIV class="igem_2018_team_content"><DIV class="igem_2018_team_column_wrapper"><DIV id="title" style="height:300px;margin-top:0px;text-align:center;color:white;background-color:rgb(83,191,213);"><SPAN style="font-size:48px;">BRAKING BAD</SPAN><SPAN id="" style="font-size:14pt;">Car Brake, Torwards a Safer CAR-T Therapy
</SPAN></DIV><DIV id="1" class="page-content" style="height:300px;margin-top:-40px;background-size:cover;background-position: center center;background-image:url(https://static.igem.org/mediawiki/2018/7/73/T--SYSU-CHINA--Home0001.png)"><SPAN style="width:50%;float:left;"><SPAN style="font-size:20px;font-weight:bold;display:block;text-align:center">CAR-T Therapy</SPAN><SPAN style="font-size:15px;display:block;text-align:justify;">
      CAR-T (chimeric antigen receptor T cell) therapy is one of the most promising treatment for cancer, with multiple ongoing clinical 
      trials worldwide and 2 therapies approved by the FDA. The therapy engineers endogenous T cells from the patients with synthetic 
      receptors for tumor antigens, giving them the ability to target tumor cells.
      </SPAN></SPAN></DIV><DIV id="2" class="page-content" style="height:300px;margin-top:-40px;background-size:cover;background-position: center center;background-image:url(https://static.igem.org/mediawiki/2018/8/8c/T--SYSU-CHINA--Home0002.png)"><SPAN style="width:50%;float:left;"><SPAN style="font-size:20px;font-weight:bold;display:block;text-align:center">The Adverse Effects</SPAN><SPAN style="font-size:15px;display:block;text-align:justify;">
      However, without proper control after administration of CAR-T cells, severe adverse effects associated with CAR-T therapy may bring 
      fatal risks to the patients, especially during the clinical trial stages. The side effects include cytokine release syndrome, on-
      target off-tumor toxicity and off-target toxicity.
      Thus, methods to control the adverse effects are urgently needed.
      </SPAN></SPAN></DIV><DIV id="3" class="page-content" style="height:300px;margin-top:-40px;background-size:cover;background-position: center center;background-image:url(https://static.igem.org/mediawiki/2018/5/50/T--SYSU-CHINA--Home0003.png)"><SPAN style="width:50%;float:left;"><SPAN style="font-size:20px;font-weight:bold;display:block;text-align:center">Current Methods</SPAN><SPAN style="font-size:15px;display:block;text-align:justify;">
      To date the prevalent ways are to engineer suicide genes in CAR-T cells and remove transferred cell population when giving drugs. 
      However, these methods could deplete CAR-T cells and completely halt the expensive treatment. Repeat the treatment may be a burden on 
      the patients, both physically and financially. 
      </SPAN></SPAN></DIV><DIV id="4" class="page-content" style="height:260px;margin-top:-40px;background-size:cover;background-position: center center;background-image:url(https://static.igem.org/mediawiki/2018/f/f7/T--SYSU-CHINA--Home0004.png)"><SPAN style="width:50%;float:left;"><SPAN style="font-size:20px;font-weight:bold;display:block;text-align:center">What We Do——Braking Bad!</SPAN><SPAN style="font-size:15px;display:block;text-align:justify;">
      This year, team SYSU-CHINA aims to provide a safer yet affordable CAR-T therapy, by developing a reversible safe switch controlled by 
      small molecules called CAR BRAKE. By expressing U24 protein of the human herpesvirus 6A under the control of tet-ON promoter, we can 
      downregulate CAR molecules on the cell surface through endosomal recycling inhibition. This could potentially be used as a universal 
      add-on for all CAR-Ts and TCR-Ts to ensure safety.
      </SPAN></SPAN></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>